Has Mary Connell received payments from drug or device companies?

Yes. Drug and device makers reported $2,884 in general payments to Mary Connell across 149 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Connell did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Connell come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Connell

Internal Medicine · Avon, INNPI 1396194403

Payments from drug & device makers

$2,884in general payments, 2019–2025

Across 149 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$514
UCB, Inc.$426
Mylan Specialty L.p.$281
Lilly USA, LLC$267
AstraZeneca$245
Bayer$169
plus $983 from 19 others

What the payments were for

Food & beverage$2,884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	32	$514
UCB, Inc.	15	$426
Mylan Specialty L.p.	16	$281
Lilly USA, LLC	15	$267
AstraZeneca	17	$245
Bayer	9	$169
Viatris Specialty LLC	6	$112
Teva Pharmaceuticals USA, Inc.	1	$106
Novo Nordisk	6	$105
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$94
Amarin Pharma, Inc.	4	$83
Exact Sciences	4	$64
Alkermes, Inc.	1	$62
Axsome Therapeutics, Inc.	2	$40
Organon	2	$37
Johnson & Johnson	2	$36
E.r. Squibb & Sons, L.L.C.	2	$35
Dexcom, Inc.	2	$34
AbbVie	1	$33
Paratek Pharmaceuticals, Inc.	2	$32
Grifols USA, LLC	2	$31
Mallinckrodt Hospital Products Inc.	1	$30
Pfizer	1	$19
Novartis	1	$15
Sumitomo Pharma America, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AUSTEDO$106

How this compares

$2,884 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	54	$59,887
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	12	$55,011
JardianceEmpagliflozin	53	$51,841
TrulicityDulaglutide	29	$35,391
EliquisApixaban	21	$23,287
FarxigaDapagliflozin Propanediol	17	$13,407
JanuviaSitagliptin Phosphate	15	$11,693
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	24	$10,872
Breo ElliptaFluticasone/Vilanterol	14	$7,298
Potassium Chloride	64	$5,327
Atorvastatin Calcium	227	$2,012
Albuterol Sulfate HfaAlbuterol Sulfate	67	$1,633
Gabapentin	64	$1,446
Metoprolol Succinate	56	$1,218
Pregabalin	15	$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$105	$59,88754 claims
Lilly USA, LLCTrulicity	$267	$35,39129 claims
PfizerEliquis	$19	$23,28721 claims
AstraZenecaFarxiga	$245	$13,40717 claims
AbbVieSynthroid	$33	$78514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Avon

Robert BuynakValparaiso$24.2M
Mohammed AllawNewburgh$3.6M
Raj VuppalanchiIndianapolis$3.4M
Phillip TothIndianapolis$3.2M
George CornettFranklin$1.3M
Ajita NarayanLafayette$951K
Abhinav SinghGreenwood$738K
Georgiann LinnemeierIndianapolis$692K
Wa'el BakdashAnderson$625K
Rita SchmidSouth Bend$599K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →